Ageing and multiple sclerosis

The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas those with later onset disease face a more rapid development of permanent disability. For people wit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet neurology Ročník 22; číslo 1; s. 66 - 77
Hlavní autoři: Graves, Jennifer S, Krysko, Kristen M, Hua, Le H, Absinta, Martina, Franklin, Robin J M, Segal, Benjamin M
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 01.01.2023
Elsevier Limited
Témata:
Adults
Age
Aging
Atrophy
Biomarkers
Brain research
Disabled Persons
Disease Progression
Epidemiology
Humans
Immune system
Lymphocytes
Multiple sclerosis
Multiple Sclerosis - therapy
Multiple Sclerosis, Chronic Progressive - drug therapy
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Myelination
Neuroprotection
Older people
Pathology
Pediatrics
ISSN:1474-4422, 1474-4465, 1474-4465
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas those with later onset disease face a more rapid development of permanent disability. For people with progressive multiple sclerosis, the poor response to current disease modifying therapies might be related to ageing in the immune system and CNS. Ageing is also associated with increased risks of side-effects caused by some multiple sclerosis therapies. Both somatic and reproductive ageing processes might contribute to development of progressive multiple sclerosis. Understanding the role of ageing in immune and neural cell function in patients with multiple sclerosis might be key to halting non-relapse-related progression. The growing literature on potential therapies that target senescent cells and ageing processes might provide effective strategies for remyelination and neuroprotection.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1474-4422
1474-4465
1474-4465
DOI:10.1016/S1474-4422(22)00184-3